{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:57:07Z","timestamp":1648760227386},"reference-count":59,"publisher":"Portland Press Ltd.","issue":"6","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,22]]},"abstract":"<jats:p>Infectious diseases are the main cause of acquired dilated cardiomyopathy. This group of disorders shares in common inflammatory cell infiltrate and myocardial remodeling. As part of its pathophysiology, there is coronary microvascular dysfunction, distinct from that observed in coronary artery disease. Chagas cardiomyopathy presents several vascular characteristics that are similar to those presented in other acquired cardiomyopathies. There is convincing evidence of the microvascular involvement and the inflammatory processes that lead to endothelial activation and ischemic damage. Current therapy for the Chagas disease is limited, and it is proposed to combine it with other pharmacological strategies that modify critical physiopathological aspects beneficial for the clinical course of the Chagas cardiomyopathy.<\/jats:p>","DOI":"10.1042\/etls20170109","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T10:15:40Z","timestamp":1513937740000},"page":"579-584","update-policy":"http:\/\/dx.doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies"],"prefix":"10.1042","volume":"1","author":[{"given":"Juan D.","family":"Maya","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Lapier","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Castillo","sequence":"additional","affiliation":[{"name":"Anatomy and Developmental Biology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Kemmerling","sequence":"additional","affiliation":[{"name":"Anatomy and Developmental Biology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Campos-Estrada","sequence":"additional","affiliation":[{"name":"Medicine Faculty, Valparaiso University, Valdivia, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Veterinary Pharmacology and Morphophysiology Institute, Veterinary Faculty, Austral University, Valdivia, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"2019102710160191900_ETLS-2017-0109CC1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","article-title":"Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention","volume":"113","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"2019102710160191900_ETLS-2017-0109CC2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.hfc.2011.08.014","article-title":"Cardiomyopathies: classification, diagnosis, and treatment","volume":"8","author":"Maisch","year":"2012","journal-title":"Heart Fail. Clin."},{"key":"2019102710160191900_ETLS-2017-0109CC3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/IJGM.S130828","article-title":"Tropical diseases of the myocardium: a review","volume":"10","author":"Groom","year":"2017","journal-title":"Int. J. Gen. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC4","first-page":"191","volume-title":"Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected tropical diseases","author":"WHO","year":"2015"},{"key":"2019102710160191900_ETLS-2017-0109CC5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/heartjnl-2016-309870","article-title":"Cardiac manifestations of parasitic diseases","volume":"103","author":"Nunes","year":"2017","journal-title":"Heart"},{"key":"2019102710160191900_ETLS-2017-0109CC6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.gheart.2015.07.006","article-title":"Prevalence and risk factors of embolic cerebrovascular events associated with Chagas heart disease","volume":"10","author":"Nunes","year":"2015","journal-title":"Glob. Heart"},{"key":"2019102710160191900_ETLS-2017-0109CC7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(09)62023-7","article-title":"Dilated cardiomyopathy","volume":"375","author":"Jefferies","year":"2010","journal-title":"Lancet"},{"key":"2019102710160191900_ETLS-2017-0109CC8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"2019102710160191900_ETLS-2017-0109CC9","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1371\/journal.pntd.0000931","article-title":"International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients","volume":"5","author":"Schijman","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2019102710160191900_ETLS-2017-0109CC10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1590\/0074-02760160334","article-title":"Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial","volume":"112","author":"Rassi","year":"2017","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"2019102710160191900_ETLS-2017-0109CC11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4330\/wjc.v6.i8.782","article-title":"Interferon-\u03b3 and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy","volume":"6","author":"Ferreira","year":"2014","journal-title":"World J. Cardiol."},{"key":"2019102710160191900_ETLS-2017-0109CC12","volume-title":"McGraw-Hill Companies. Hurst's the Heart","author":"Hurst","year":"2011"},{"key":"2019102710160191900_ETLS-2017-0109CC13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/heartjnl-2013-304291","article-title":"Coronary microvascular dysfunction in primary cardiomyopathies","volume":"100","author":"Spoladore","year":"2014","journal-title":"Heart"},{"key":"2019102710160191900_ETLS-2017-0109CC14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/hc0202.102119","article-title":"Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction","volume":"105","author":"Neglia","year":"2002","journal-title":"Circulation"},{"key":"2019102710160191900_ETLS-2017-0109CC16","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1371\/journal.pntd.0000674","article-title":"Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms","volume":"4","author":"Rossi","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2019102710160191900_ETLS-2017-0109CC17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1590\/0037-8682-0028-2013","article-title":"Pathogenesis of chronic Chagas cardiomyopathy: the role of coronary microvascular derangements","volume":"46","author":"Marin-Neto","year":"2013","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"2019102710160191900_ETLS-2017-0109CC18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12968-015-0200-7","article-title":"Myocardial tissue characterization in Chagas\u2019 heart disease by cardiovascular magnetic resonance","volume":"17","author":"Torre\u00e3o","year":"2015","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"2019102710160191900_ETLS-2017-0109CC19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/echo.12364","article-title":"Impaired coronary flow reserve in patients with indeterminate form of Chagas\u2019 disease","volume":"31","author":"Rabelo","year":"2014","journal-title":"Echocardiography"},{"key":"2019102710160191900_ETLS-2017-0109CC20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jcmg.2008.09.012","article-title":"Changes in myocardial perfusion correlate with deterioration of left ventricular systolic function in chronic Chagas\u2019 cardiomyopathy","volume":"2","author":"Hiss","year":"2009","journal-title":"JACC Cardiovasc. Imaging"},{"key":"2019102710160191900_ETLS-2017-0109CC21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1590\/S0036-46651999000200011","article-title":"Microcirculation and Chagas\u2019 disease: hypothesis and recent results","volume":"41","author":"Ramos","year":"1999","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"2019102710160191900_ETLS-2017-0109CC22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4269\/ajtmh.1985.34.246","article-title":"Abnormalities of the coronary microcirculation in acute murine Chagas\u2019 disease","volume":"34","author":"Factor","year":"1985","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2019102710160191900_ETLS-2017-0109CC23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1476-5381.2011.01609.x","article-title":"Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy","volume":"165","author":"Andrade","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"2019102710160191900_ETLS-2017-0109CC24","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1128\/IAI.73.4.2496-2503.2005","article-title":"Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease","volume":"73","author":"Tanowitz","year":"2005","journal-title":"Infect. Immun."},{"key":"2019102710160191900_ETLS-2017-0109CC25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1084\/jem.20062432","article-title":"Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection","volume":"204","author":"Ashton","year":"2007","journal-title":"J. Exp. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC26","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00436-013-3444-x","article-title":"Protection of vascular endothelium by aspirin in a murine model of chronic Chagas\u2019 disease","volume":"112","author":"Molina-Berrios","year":"2013","journal-title":"Parasitol. Res."},{"key":"2019102710160191900_ETLS-2017-0109CC27","first-page":"757","article-title":"Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease","volume":"21","author":"Golias","year":"2007","journal-title":"In Vivo"},{"key":"2019102710160191900_ETLS-2017-0109CC28","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/oby.2008.331","article-title":"Trypanosoma cruzi infection of cultured adipocytes results in an inflammatory phenotype","volume":"16","author":"Nagajyothi","year":"2008","journal-title":"Obesity"},{"key":"2019102710160191900_ETLS-2017-0109CC29","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1371\/journal.pntd.0001867","article-title":"Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10","volume":"6","author":"Nogueira","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2019102710160191900_ETLS-2017-0109CC30","author":"Fernandes FVM","year":"2017"},{"key":"2019102710160191900_ETLS-2017-0109CC31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic, T. cruzi carriers: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"2019102710160191900_ETLS-2017-0109CC33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1128\/AAC.01401-12","article-title":"Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease","volume":"57","author":"Pinazo","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2019102710160191900_ETLS-2017-0109CC34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/jac\/dks027","article-title":"Safety of benznidazole use in the treatment of chronic Chagas\u2019 disease","volume":"67","author":"Hasslocher-Moreno","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"2019102710160191900_ETLS-2017-0109CC35","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMc1514453#SA3","article-title":"Benznidazole for chronic chagas\u2019 cardiomyopathy","volume":"374","author":"Urbina","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2017.03.611","article-title":"Pharmacodynamics and follow-up period in the treatment of human Trypanosoma cruzi infections with posaconazole","volume":"70","author":"Urbina","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"2019102710160191900_ETLS-2017-0109CC38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijcard.2012.01.033","article-title":"Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy","volume":"167","author":"Vilas Boas","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2019102710160191900_ETLS-2017-0109CC39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/S0066-782X2011005000112","article-title":"Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy","volume":"97","author":"Barbosa","year":"2011","journal-title":"Arq. Bras. Cardiol."},{"key":"2019102710160191900_ETLS-2017-0109CC40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.taap.2016.11.015","article-title":"Benznidazole, the trypanocidal drug used for Chagas disease, induces hepatic NRF2 activation and attenuates the inflammatory response in a murine model of sepsis","volume":"315","author":"Lambertucci","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2019102710160191900_ETLS-2017-0109CC41","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.molimm.2010.06.002","article-title":"Benznidazole blocks NF-\u03baB activation but not AP-1 through inhibition of IKK","volume":"47","author":"Manarin","year":"2010","journal-title":"Mol. Immunol."},{"key":"2019102710160191900_ETLS-2017-0109CC42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1476-5381.2010.00952.x","article-title":"Over-expression of mitogen-activated protein kinase phosphatase-2 enhances adhesion molecule expression and protects against apoptosis in human endothelial cells","volume":"161","author":"Al-Mutairi","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"2019102710160191900_ETLS-2017-0109CC43","first-page":"323","article-title":"Chagas disease: present status of pathogenic mechanisms and chemotherapy","volume":"43","author":"Maya","year":"2010","journal-title":"Biol. Res."},{"key":"2019102710160191900_ETLS-2017-0109CC44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.exppara.2009.09.005","article-title":"Trypanosoma cruzi: in vitro effect of aspirin with nifurtimox and benznidazole","volume":"124","author":"L\u00f3pez-Mu\u00f1oz","year":"2010","journal-title":"Exp. Parasitol."},{"key":"2019102710160191900_ETLS-2017-0109CC45","doi-asserted-by":"publisher","first-page":"e2173","DOI":"10.1371\/journal.pntd.0002173","article-title":"Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: evidence of a 15-epi-lipoxin A4-mediated effect","volume":"7","author":"Molina-Berrios","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2019102710160191900_ETLS-2017-0109CC46","doi-asserted-by":"publisher","first-page":"e0003770","DOI":"10.1371\/journal.pntd.0003770","article-title":"Simvastatin and benznidazole-mediated prevention of Trypanosoma cruzi-induced endothelial activation: role of 15-epi-lipoxin A4 in the action of simvastatin","volume":"9","author":"Campos-Estrada","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2019102710160191900_ETLS-2017-0109CC47","doi-asserted-by":"publisher","first-page":"e02137-16","DOI":"10.1128\/AAC.02137-16","article-title":"Simvastatin attenuates endothelial activation through 15-epi-lipoxin A4 production in murine chronic Chagas cardiomyopathy","volume":"61","author":"Gonz\u00e1lez-Herrera","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"2019102710160191900_ETLS-2017-0109CC48","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4269\/ajtmh.2011.10-0451","article-title":"Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs","volume":"84","author":"Melo","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2019102710160191900_ETLS-2017-0109CC49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","article-title":"Pleiotropic effects of statin therapy: molecular mechanisms and clinical results","volume":"14","author":"Wang","year":"2008","journal-title":"Trends Mol. Med."},{"key":"2019102710160191900_ETLS-2017-0109CC50","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1093\/eurheartj\/ehu244","article-title":"The Notch pathway: a novel target for myocardial remodelling therapy","volume":"35","author":"Ferrari","year":"2014","journal-title":"Eur. Heart J."},{"key":"2019102710160191900_ETLS-2017-0109CC51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1161\/STROKEAHA.108.524116","article-title":"Simvastatin increases notch signaling activity and promotes arteriogenesis after stroke","volume":"40","author":"Zacharek","year":"2009","journal-title":"Stroke"},{"key":"2019102710160191900_ETLS-2017-0109CC52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/1414-431X20133177","article-title":"Role of Notch signaling in the mammalian heart","volume":"47","author":"Zhou","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"2019102710160191900_ETLS-2017-0109CC53","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jacc.2017.08.004","article-title":"Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment","volume":"70","author":"Bocchi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"2019102710160191900_ETLS-2017-0109CC54","doi-asserted-by":"publisher","first-page":"CD009077","DOI":"10.1002\/14651858.CD009077","article-title":"Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy","volume":"7","author":"Mart\u00ed-Carvajal","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"2019102710160191900_ETLS-2017-0109CC55","doi-asserted-by":"publisher","first-page":"CD009077","DOI":"10.1002\/14651858.CD009077.pub2","article-title":"Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy","volume":"11","author":"Hidalgo","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"2019102710160191900_ETLS-2017-0109CC56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jeu.12184","article-title":"Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives","volume":"62","author":"Urbina","year":"2015","journal-title":"J. Eukaryot. Microbiol."},{"key":"2019102710160191900_ETLS-2017-0109CC57","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1586\/14779072.2015.1103648","article-title":"Developments in the management of Chagas cardiomyopathy","volume":"13","author":"Tanowitz","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2019102710160191900_ETLS-2017-0109CC58","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4269\/ajtmh.15-0237","article-title":"Enalapril in combination with benznidazole reduces cardiac inflammation and creatine kinases in mice chronically infected with Trypanosoma cruzi","volume":"93","author":"Penitente","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2019102710160191900_ETLS-2017-0109CC59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas disease","volume":"156","author":"Bermudez","year":"2016","journal-title":"Acta Trop."}],"container-title":["Emerging Topics in Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/emergtoplifesci\/article-pdf\/1\/6\/579\/483973\/etls-2017-0109c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/emergtoplifesci\/article-pdf\/1\/6\/579\/483973\/etls-2017-0109c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T14:16:09Z","timestamp":1572185769000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article\/1\/6\/579\/11561\/Chronic-Chagas-cardiomyopathy-a-therapeutic"}},"subtitle":[],"editor":[{"given":"Roberto","family":"Docampo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,12,22]]},"published-print":{"date-parts":[[2017,12,22]]}},"URL":"https:\/\/doi.org\/10.1042\/etls20170109","relation":{},"ISSN":["2397-8554","2397-8562"],"issn-type":[{"value":"2397-8554","type":"print"},{"value":"2397-8562","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]}}}